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Nuclear receptors (NRs) play central roles in metabolic syndrome, making them attractive drug targets
despite the challenge of achieving functional selectivity. For instance, members of the thiazolidinedione class
of insulin sensitizers offer robust efficacy but have been limited due to adverse effects linked to activation of
genes not involved in insulin sensitization. Studies reviewed here provide strategies for targeting subsets of
PPARg target genes, enabling development of next-generation modulators with improved therapeutic index.
Additionally, emerging evidence suggests that targeting the NRsROR andRev-erb holds promise for treating
metabolic syndrome based on their involvement in circadian rhythm and metabolism.Metabolic Disorders
The percentage of the global population categorized as obese
has skyrocketed over the last two decades. This trend is pre-
dicted to continue as developing nations increasingly adopt
more sedentary lifestyles and gain easier access to high-calorie
diets. As recently as 10 years ago in the United States, obese
adults (defined as BMI >30) made up less than 12% of the pop-
ulation. Now more than 20% of the adult population meets the
CDC criteria for obesity, and greater than 40% are considered
overweight. Metabolic syndrome is characterized as a clus-
tering of factors associated with an increased risk of cardiovas-
cular disease and stroke, and is becoming more common
(Moller and Kaufman, 2005). The essential risk factors that
constitute metabolic syndrome are age, atherogenic dyslipide-
mia (high triglycerides and low HDL-C), hypertension, elevated
plasma glucose, a prothrombotic state, and a proinflammatory
state. According to current views, there are two major underly-
ing causes of metabolic syndrome: obesity and type 2 diabetes
mellitus (T2DM) (Grundy et al., 2005). Obesity is conceptually
defined as an excess of body lipid of sufficient magnitude to
impair health and longevity. T2DM is a chronic metabolic disor-
der that results partly in the inability of the body to respond
adequately to circulating insulin, a condition termed insulin
resistance. The comorbidities of metabolic syndrome will
continue to strain global health care systems and require the
development of alternative strategies to combat this epidemic.
The current standard of care for treating metabolic syndrome
includes pharmacologic intervention and lifestyle modification
such as nutritional consultation and modification of diet,
rigorous weight control, and increased regular exercise.
Modest weight loss can result in an improvement in metabolic
parameters (Grundy et al., 2004). However, weight loss and ex-
ercise often are not sufficient due to poor compliance and
perhaps confounding genetic factors (Bouchard, 1988; Moller
et al., 1996). Pharmacologic approaches have focused on the
use of combination therapy for diabetes treatment in an effort
to postpone the inevitable need for insulin therapy (Gavin,2006). Therapeutic strategies to directly combat obesity have
demonstrated successful outcomes in the clinic by suppressing
either appetite or absorption of calories (Berlie and Hurren,
2013; Carter et al., 2012; Hung et al., 2010); however, adverse
effects and other challenges persist with these approaches
(Bloom et al., 2008; Heal et al., 2009; Jain et al., 2011). Recent
efforts to target obesity have expanded to therapeutic ap-
proaches that include restoring dysregulated circadian rhythms
that are associated with obesity (Maury et al., 2010), and induc-
tion of brown adipose tissue (BAT) or browning of white adi-
pose tissue (WAT) resulting in dissipation of energy as heat
(Seale and Lazar, 2009). Many of these strategies evolved
from our increased understanding of nuclear receptor (NR)
function, and they represent opportunities for therapeutic
development.
Nuclear Receptors as Therapeutic Targets forMetabolic
Syndrome
NRs are a unique superfamily of ligand-dependent transcription
factors that control a diverse set of biological activities by trans-
lating dietary and endocrine signals into changes in expression
of gene networks. NRs are attractive therapeutic targets for the
treatment of metabolic syndrome because their dysfunction
due to naturally occurring mutations can result in metabolic dis-
orders (Gurnell, 2003; Hegele et al., 2002; Savage et al., 2003),
and their activity can be robustly modulated by small lipophilic
molecules that can be substituted by exogenous synthetic
small molecules. NRs are the molecular target of approximately
10%–15% of drugs currently approved by the FDA, highlighting
their tractability for therapeutic intervention (Overington et al.,
2006).
There are 48 NRs in the human genome that are all thought to
share a common evolutionary origin as evidenced by the signif-
icant sequence homology and conserved cellular function
across the superfamily (Figure 1). NRs are characterized by a
multidomain architecture comprised of an N-terminal ligand-
independent Activating Function 1 (AF1) domain, DNA-bindingCell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc. 193
Figure 1. Sequence Alignment of Nuclear Receptor Superfamily
Alignment of all 48 humanNR receptors demonstrates significant conservation of the DBD and LBD across the superfamily, with significant divergence of the A/B,
Hinge, and F domains. All receptors are aligned by their DNA binding domains and are drawn to scale based on length of amino acid sequence.
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ing the ligand-dependent AF2 (Evans, 1988). The AF1 and hinge
are the most divergent in sequence and length across the super-
family and are considered intrinsically disordered (Krasowski
et al., 2008), and their function and significance have been
reviewed previously (Clinckemalie et al., 2012; Moore et al.,
2006; Tremblay et al., 1999; Wa¨rnmark et al., 2003; Zwart
et al., 2010). The DBD is the most highly conserved sequence
among NRs and contains two zinc-finger motifs to bind distinct
DNA response elements. NR response elements are commonly
arranged as either direct or inverted repeats of a consensus
half-site (RGGTCA; R = purine). NRs can bind DNA as mono-
mers, homodimers, or heterodimers with a member of the
retinoid X receptor (RXR) subfamily.
The LBD is often the focus of drug-discovery efforts and is
structurally conserved across the superfamily and is described
as having three stacked a-helical sheets that create an internal
hydrophobic cavity to which small-molecule ligands can bind
(Moore et al., 2006). The ligand-dependent AF2 structural
element contained in the LBD is the surface of the receptor
directly involved in interactions with coactivator and corepressor
proteins that either have intrinsic chromatin remodeling activity
or tether in such enzymes. Coactivator proteins contain a com-
mon LXXLL motif known as ‘‘NR boxes,’’ which interact at AF2
when the receptor is in an active conformation (Heery et al.,
1997). Coactivators like steroid receptor coactivator 1 (SRC-1)
can act locally to acetylate histones, unraveling DNA and allow-194 Cell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc.ing recruitment of the basal transcription complex to the initiation
site of NR target genes (Spencer et al., 1997). In contrast,
corepressor proteins like the NR corepressor (NCoR) and
silencing mediators of retinoid and thyroid (SMRT) contain an
L/IxxI/VI motif referred to as ‘‘CoRNR boxes,’’ which interact
with high affinity at AF2 when the receptor is in the inactive
conformation (Hu and Lazar, 1999). SMRT and NCoR recruit his-
tone deacetylase 3 (HDAC3), which keeps chromatin compact
leading to repression of basal transcriptional activity (Privalsky,
2004).
NR Ligand Binding
NRs are classified as ligand-dependent transcription factors, as
changes in their conformational dynamics induced by binding
ligand ultimately drive downstream transcriptional events. In
the apo state, NRs typically have high affinity for corepressor
leading to transcriptional repression. Activation of NRs by
agonist ligands occurs primarily through conformational
changes in AF2 that displace corepressor and recruit coactiva-
tors. Alternatively, ligands that repress NR transcriptional
activity below basal level through recruitment of corepressor
are termed inverse agonists (Germain et al., 2006). The
Rev-erb subfamily of ‘‘constitutive repressors’’ is an exception,
as repressive ligands that induce increased affinity for NCoR
are considered agonists (Woo et al., 2007).
Over the past two decades it has become clear that there is
significantly more complexity to the functional regulation of
Figure 2. Mechanisms of PPARg Functional Control
Ligand-mediated control of PPARg can be achieved through classical AF2
activation, modulation of PTM status, RXRa, cofactor, and DNA affinity.
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differentially affect the conformational dynamics of AF2 leading
to various degrees of activation but can also impact NR affinity
for DNA (Thuillier et al., 1998; Zhang et al., 2011), receptor degra-
dation (Hauser et al., 2000), interaction with cofactor proteins
(Ohno et al., 2012), and modulation of posttranslational modifi-
cation (PTM) status (Choi et al., 2010; Choi et al., 2011), a central
focus of this review (Figure 2). NR ligands can also demonstrate
tissue-specific effects as a result of differing cofactor popula-
tions, NR subtypes, and isoforms (Stossi et al., 2004; Tee
et al., 2004). This exceptional biological complexity in response
to ligand binding is the primary challenge of translating readily
identifiable, high-affinity NR ligands into clinical therapeutics.
Understanding this complexity may afford the opportunity to
develop functional selective modulators that translate into
improved drugs. Here we review the evolution of PPARg tar-
geted ligands for the treatment of T2DM from blunt
instruments (super agonists) that carry significant adverse
effects, to next-generation ligand classes that selectively modu-
late receptor function with improved therapeutic index. Similar
strategies will likely apply to therapeutic development efforts
for ROR and Rev-erb targeted ligands, for which recent studies
reviewed here demonstrate promise for the treatment of meta-
bolic syndrome.
The PPAR Subfamily of NRs
The peroxisome proliferator-activated receptor (PPAR) NR sub-
family was identified with the discovery that a diverse class of
rodent hepatocarcinogens induced proliferation of peroxisomes
(Issemann and Green, 1990). Three PPAR subtypes have been
identified—PPARa (NR1C1), PPARb/d (NR1C2), and PPARg
(NR1C3)—each with unique expression profiles, ligand speci-
ficity, and functional roles (Berger and Moller, 2002). These
receptors regulate transcriptional activity by forming obligate
heterodimers with RXR and binding to specific DNA response
elements (PPREs) that consist of two repeats of the core
AGGTCA sequence separated by one nucleotide (DR-1) in the
promoter or enhancer regions of their target genes (Kliewer
et al., 1992; Mangelsdorf and Evans, 1995).PPARa is a major regulator of lipid metabolism in the liver and
is activated under conditions of energy deprivation and pro-
longed fasting to initiate ketogenesis (Kersten et al., 1999). Acti-
vation of PPARa by synthetic ligands, including the fibrate drugs
used to treat hyperlipidemia, promote uptake, utilization, and
catabolism of fatty acids via increased expression of classic
target genes PDK4, ACOX1, and CPT1 (Rakhshandehroo
et al., 2010; Staels et al., 1998). The therapeutic potential of
PPARa for the treatment of metabolic syndrome has been
reviewed previously (Cheng and Leiter, 2008; Hiukka et al.,
2010; Staels and Fruchart, 2005).
PPARd (also called PPARb) is highly expressed in intestinal
epithelium, liver, and keratinocytes, consistent with its significant
biological role in these tissues, and is also detected at lower
levels in the brain, skin, kidney, lung, and testes (Girroir et al.,
2008). It has been reported that forced PPARd activation in trans-
genic models protects against obesity and induces an exercise-
like metabolic status, spurring interest in the development of
PPARd modulators for the treatment of metabolic syndrome
(Wang et al., 2004). Studies in animals and humans demonstrate
that PPARd activation with synthetic ligands like GW501516
exerts desirable effects that include reduced weight gain,
increased skeletal muscle metabolic rate and endurance,
improved insulin sensitivity, and reduced atherogenic inflamma-
tion (Rise´rus et al., 2008; Tanaka et al., 2003). The potential of
PPARd as a therapeutic target for the treatment of metabolic
syndrome has been reviewed previously (Reilly and Lee, 2008).
PPARg is the most well-characterized member of the PPAR
subfamily, as its central role in glucose metabolism and fatty
acid storage has made it a desirable pharmacological target.
There are two PPARg isoforms, PPARg1, which is expressed
ubiquitously except for muscle, and PPARg2, which is ex-
pressed primarily in WAT under normal metabolic conditions
(Fajas et al., 1997). PPARg2 is often called the ‘‘master regulator
of adipogenesis’’ because it is required to drive the terminal dif-
ferentiation of preadipocytes toward maturation (Chandra et al.,
2008). Fat-specific PPARg knockout mice fail to generate adi-
pose tissue in response to high-fat diet, demonstrating the
receptors’ critical role in regulating fatty acid storage and
glucose metabolism (Jones et al., 2005). The proper function of
PPARg is critical to metabolic homeostasis, as genetic variants
in humans can lead to familial partial lipodystrophy, an extreme
monogenic form of metabolic syndrome (Jeninga et al., 2009).
Interestingly, no general defects are observed in transgenic het-
erozygote PPARg knockout mice that demonstrate protection
from high-fat-diet-induced obesity, fatty liver, and insulin resis-
tance as a result of reduced triglyceride content in WAT, skeletal
muscle, and liver (Akune et al., 2004; Kubota et al., 1999;
Yamauchi et al., 2001). Activation of PPARg by endogenous
ligands which may include polyunsaturated fatty acids (Kliewer
et al., 1997; Krey et al., 1997), prostanoids like 15-deoxy-
D12,14 prostaglandin J2 (15-dPGJ2) (Forman et al., 1995;
Kliewer et al., 1995), and oxidized fatty acids like 9-HODE and
13-HODE (Nagy et al., 1998) leads to increased expression of
many target genes including aP2, GLUT4, PEPCK, C/EBP,
Adipsin, and adiponectin (Perera et al., 2006; Tontonoz et al.,
1994a, 1994b, 1995). The promiscuity of PPARg activation is a
major challenge of avoiding adverse effects when pharmaco-
logically targeting the receptor, and therapeutic developmentCell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc. 195
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genes by harnessing tissue-specific effects (Festuccia et al.,
2009; Montague, 2002; Zı´dek et al., 2013) and nonclassical
AF2 mechanisms of receptor control (Ahmadian et al., 2013;
Cariou et al., 2012; Rosenson et al., 2012).
PPARg Is the Pharmacological Target of the TZDs
PPARg is the pharmacological target of the antidiabetic thiazoli-
dinediones (TZDs) class of drugs that include rosiglitazone
(Avandia) and pioglitazone (Actos) (Lehmann et al., 1995). The
precursor lead to the TZDs, 2-chloro-3-phenylpropanoic acid
ethyl ester (AL-294), was discovered through in vivo screening
efforts against insulin-resistant rodent models (Ikeda et al.,
1981; Iwatsuka et al., 1970; Kawamatsu et al., 1980). As such,
the molecular target of the TZDs and their mechanism of action
were unknown until several years after their discovery (Lehmann
et al., 1995). TZDs have proven robust as insulin sensitizers and
work synergistically with other T2DM therapeutic approaches
(Elte and Blickle´, 2007; Garber et al., 2007; Hanefeld, 2007;
Zinman et al., 2007, 2009). Themechanismbywhich TZDs derive
efficacy is not fully understood but is thought to be through a
combination of induction of insulin-sensitizing adipokines, anti-
inflammatory effects, and fatty acid partitioning from muscle to
adipocytes (Girard, 2001; Martin et al., 1998; Saraf et al.,
2012). These drugs have also been shown to have positive
effects on cardiovascular disease (Hamblin et al., 2009; Plutzky,
2011), Alzheimer’s disease (Heneka et al., 2011), Parkinson’s
disease (Carta et al., 2011), cancer (Blanquicett et al., 2008),
and the browning of fat (Ohno et al., 2012) through various
PPARg-mediated mechanisms. Unfortunately, concerns over
adverse side effects including weight gain (Fonseca, 2003),
edema (Nesto et al., 2003), plasma volume expansion (PVE)
(Staels, 2005), increased risk of congestive heart failure (Nesto
et al., 2003), and bone fracture (Aubert et al., 2010) have limited
their utility. In particular, rosiglitazone has been restricted or
withdrawn from most markets due to the increased incidence
ofmyocardial infarction, likely a result of increased backpressure
on the heart due to edema and PVE (Hsiao et al., 2009; Lips-
combe et al., 2007; Loke et al., 2011). Pioglitazone, a compara-
tively less potent PPARg agonist with modest PPARa activity,
has demonstrated improved cardiovascular outcomes,
providing a potential mechanistic explanation for this improved
therapeutic index (Juurlink et al., 2009; Winkelmayer et al.,
2008). Based on these findings, efforts have focused on the
pharmacological development of a class of ‘‘selective PPARg
modulators’ (SPPARMs).
SPPARMs and the PPARg Paradox
SPPARMs display reduced transcriptional activity in reporter
assays (partial agonists), exhibit potent insulin sensitization on
the same order as TZDs, and are anitiadipogenic with reduced
adverse effects in animal models (Rangwala and Lazar, 2002).
Importantly, SPPARMs demonstrate that the insulin-sensitizing
effects of PPARg-targeted ligands can be separated from the
adverse adipogenic effects. Several SPPARMs have advanced
into clinical trials and may hold therapeutic promise (Gregoire
et al., 2009; Motani et al., 2009); however, mechanistically they
create a paradox. If PPARg-targeted ligands derive antidiabetic
efficacy by activating the receptor, why do these poor agonists196 Cell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc.retain comparable antidiabetic efficacy to full agonist TZDs?
And to the broader point, why is synthetic activation of PPARg
so effective at insulin sensitization, when many obese and
diabetic patients that respond to TZDs have no defects in the
receptor?
Posttranslational Modification of PPARg
Some aspects of the PPARg paradox were addressed by the
discovery that inflammatory cytokines associated with obesity
activate the protein kinase cyclin-dependent kinase 5 (Cdk5),
resulting in phosphorylation of PPARg at S273 (pS273) (Choi
et al., 2010). This modification of PPARg correlated with repres-
sion of a subset of target genes shown to be dysregulated in
obesity, including repression of the insulin-sensitizing adipokine,
adiponectin. The efficacy of antidiabetic PPARg ligands such as
rosiglitazone and the partial agonist MRL24 were shown to
correlate with their ability to block pS273, independent of clas-
sical receptor transcriptional agonism (Choi et al., 2010; Rocchi
et al., 2001). Based on these findings, an alternative class of
high-affinity PPARg-targeting insulin sensitizers was developed
that effectively block pS273 while avoiding classical AF2-driven
receptor activation, termed functional selective PPARgmodula-
tors (FSPPARMs). SR1664 is a representative compound from
this class that, in terms of insulin sensitization, was shown to
be equally efficacious as rosiglitazone, without causing weight
gain or hemodilution in vivo (Choi et al., 2011). SR1664 was
derived from the potent partial agonist SPPARM GSK538
(Lamotte et al., 2010) and was designed to actively antagonize
the receptor through an AF2 clash to ablate classical agonism
as previously described for the estrogen receptor (Brzozowski
et al., 1997; Shiau et al., 1998). Thus, this class of compounds
is functionally selective in that they are devoid of classical AF2
agonism (do not drive expression of adipogenic genes) yet
potently modulate a specific PTM to control expression of a
unique subset of PPARg target genes.
The picture that emerges from these findings is that the design
of compounds targeting PPARg must move beyond the tradi-
tional paradigm of agonist/antagonist and include a focus on
the modulation of PTMs. Recent work from the Manglesdorf
and Kliewer labs suggesting a path toward more selective mod-
ulators has demonstrated that both beneficial and adverse
effects of TZDs are a product of the induced expression of Fibro-
blast Growth Factor-21 (FGF21) and its ability to modulate
receptor activity through SUMOylation of K107 (Dutchak et al.,
2012; Qiang and Accili, 2012). A thorough review of PPARg
PTMs to AF1 has previously been published (van Beekum
et al., 2009). Here we focus on PTMs to the ligand binding
domain that have been demonstrated to be modulated by
synthetic ligand binding as strategies for targeting metabolic
syndrome.
SUMOylation of the PPARg LBD Leads to Repression
of NFkB Inflammatory Genes
Efforts to elucidate themechanism bywhich PPARg agonists are
capable of simultaneously activating PPARg and repressing
NFkB target genes led to the discovery of a SUMOylation site
at lysine 365 on the ligand binding domain (Pascual et al.,
2005). Rosiglitazone and the SPPARM GW00072 were reported
to promote SUMOylation of the receptor, targeting PPARg to the
Cell Metabolism
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This association prevents ubiquitylation and proteosomal degra-
dation of the repressor complex that would typically lead to
target gene activation, instead maintaining a repressed state
(Pascual et al., 2005). Ligand-induced repression of these
NFkB inflammatory target genes is associated with the desirable
antidiabetic and antiatherogenic efficacy of rosiglitazone. This
finding highlights the multiple roles of PPARg, which acts not
only as a transcription factor to activate its own target genes
but also as a cofactor capable of regulating the activity of other
transcription factors.
Acetylation of the PPARg LBD Controls Induction
of Brown Adipose Tissue
Adipose tissue in mammals can be distinguished as either WAT
used to store excess energy or BAT that acts to dissipate energy
in the form of heat. The strategy to promote the development of
BAT pharmacologically is conceptually appealing as a defense
against obesity and has been demonstrated viable in animal
models (Enerba¨ck, 2010; Fukui et al., 2000; Sell et al., 2004;
Wilson-Fritch et al., 2003) and in humans (Bogacka et al.,
2005). PPARg ligands have been shown to drive the conversion
of WAT to BAT bymodulating association with PRDM16, a factor
that controls the development of classical brown fat (Ohno et al.,
2012). Despite the observation that full agonist TZDs are
most efficacious at driving the ‘‘browning’’ effect, efforts to
develop functional selective ligands with improved therapeutic
index are buoyed by the finding that the association of
PPARg:PRDM16 is regulated by recently identified PTMs (Qiang
et al., 2012).
Two acetylation sites on the PPARg ligand binding domain
(lysine 268 and lysine 293) were recently identified in a report
addressing the mechanism by which NAD-dependent deacety-
lase SirT1 gain of function mimics the insulin-sensitizing and
‘‘browning’’-of-WAT effects associated with TZDs (Qiang et al.,
2012). The acetylation state of these sites was found to be asso-
ciated with physiological cues such as low temperature, which
triggers reduced acetylation and increased browning of WAT,
while high-fat diet led to increased acetylation, reduced SirT1
association, and decreased insulin sensitivity. The TZDs rosigli-
tazone and troglitazone were both reported to increase associa-
tion of PPARg:SirT1, reducing acetylation of both K268 and
K293. Site-directed mutagenesis studies revealed that deacety-
lation of K293 was requisite for association of PPARg with
PRDM16, while K268 PTM status had no effect. However,
acetylation of both lysines was required to associate with
NCoR, while deacetylation of either site was sufficient to
displace. These findings provide a potential strategy for devel-
oping functional SPPARMs that drive the conversion of WAT to
BAT by modulating acetylation of the receptor while avoiding
AF2 activation that would lead to induction of adipogenesis
and the associated adverse effects of TZDs.
Development of PPARg Structure Activity Relationship
Significant efforts have been made to structurally characterize
the interaction between PPARg and synthetic ligands to develop
optimized therapeutics and better characterize the functional
differences between TZDs, SPPARMs, and FSPPARMs. Several
cocrystal structures of isolated PPARg LBD bound to represen-tative synthetic ligands have been reported, leading to the obser-
vation that full agonist TZDs and non-TZDs like MRL20 make a
conserved hydrogen bond with Y473 on helix 12, while partial
agonist SPPARMs do not (Bruning et al., 2007; Einstein et al.,
2008; Nolte et al., 1998). These crystal structures have been
valuable in identifying differences between TZDs and SPPARMs;
however, no large-scale changes in the global protein fold of
PPARg have been observed to explain the differential effects
on corepressor and coactivator affinities (Bruning et al., 2007).
The full-length crystal structure of PPARg in complex with
RXRa and DNA was a significant achievement and provided
the first insight into the interplay between various receptor
domains, DNA, and ligands (Chandra et al., 2008). However,
solution structures of the same full-length PPARg complex
obtained using SAXS, SANS, and FRET demonstrate an
extended asymmetric shape highlighting the dynamic nature of
these interactions and the importance of utilizing complimentary
structural approaches when developing structure activity rela-
tionships (SAR) (Rochel et al., 2011). It is important to note that
none of these structures have been solved for the various
PTMs of the receptor mentioned above.
In efforts to better understand the complexity of functional
response induced by ligand binding, hydrogen/deuterium
exchange mass spectrometry (HDX-MS) has been applied to
characterize changes in protein dynamics (Bruning et al., 2007;
Dai et al., 2008, 2009; Wright et al., 2011; Zhang et al., 2010,
2011). Some of these studies have demonstrated that the degree
to which ligand binding stabilizes the AF2 domain correlates with
receptor activation (Bruning et al., 2007; Choi et al., 2011), while
other modulators stabilize different regions of the LBD. This
approach has been used to demonstrate that at least some
partial-agonist SPPARMs activate PPARg using a helix 12-
independent mechanism (Bruning et al., 2007), a finding now
supported by other reports (Klein et al., 2005; Puigserver et al.,
1998; Waku et al., 2010). NMR studies have also demonstrated
that ligand and receptor dynamics on a subsecond timescale
affect the graded transcriptional output of PPARg modulators
(Hughes et al., 2012). The application of complimentary struc-
tural approaches will continue to be critical in understanding
the complex functional control of PPARg and other NRs by
endogenous and synthetic ligands.
Rev-erbs and RORs: Regulators of Circadian Rhythm,
Lipid Homeostasis, and Metabolism
Circadian rhythm is a biological process that displays a pattern
of daily oscillation, is controlled by endogenous factors, and is
entrainable. Circadian oscillations are necessary for an organ-
ism’s survival, as they allow the anticipation and adaptation to
predictable changes in light/dark cycles, activity/rest cycles,
and feeding times. The central circadian clock is located in the
suprachiasmatic nucleus within the hypothalamus and directly
receives environmental cues from ganglion cells in the retina
(Green et al., 2008). Disturbances of the circadian clock have
been associated with increased incidence of obesity, diabetes,
and other disorders (Gachon et al., 2004; Sahar and Sassone-
Corsi, 2009; Weldemichael and Grossberg, 2010). Hormones
and adipokines are expressed and secreted in a circadian rhyth-
mic fashion; however, their expression patterns in obese animals
and humans are distorted (Ando et al., 2005; Yildiz et al., 2004).Cell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc. 197
Figure 3. Nuclear Receptors and Circadian
Rhythm
Members of the PPAR, ROR, and Rev-erb NR
subfamilies regulate circadian rhythms and
expression of core clock genes. Therapeutic
targeting of these NRs to normalize dysregulated
circadian rhythm may afford a treatment strategy
for metabolic syndrome.
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sleep and eating times, disproportionately display impaired insu-
lin sensitivity, higher body mass, and hypertension highlights the
correlation between proper circadian clock oscillation andmeta-
bolic homeostasis (Gangwisch et al., 2005; Rudic et al., 2004).
Metabolic control of the circadian rhythm starts with the olig-
omerization and binding of core clock activators brain and
muscle aryl hydrocarbon receptor nuclear translocator (ARNT)-
like protein 1 (BMAL1), circadian locomotor output cycles kaput
(CLOCK), and neuronal PAS domain protein 2 (NPAS2) to E box
(50-CACGTC-30) enhancer elements (Church et al., 1985;
DeBruyne et al., 2007; Gachon et al., 2004; Hao et al., 1997).
This event drives the activation of several clock genes, including
Per and Cry, which heterodimerize, and at critical concentrations
can translocate into the nucleus repressing BMAL1/CLOCK,
completing the negative feedback loop in a circadian pattern
(Ko and Takahashi, 2006). Environmental cues such as light,
temperature, and food can induce the rapid activation of cyclic
AMP production, Ca2+ signaling, and MAPK pathway, leading
to induction of Per and Cry genes and demonstrating the com-
plex interplay of circadian factors that control energy balance,
feeding behavior, and metabolic processes (Hirota and Fukada,
2004; Panda et al., 2002; Storch et al., 2002).
The RORs and Rev-erbs are considered core clock machinery
because they regulate the cyclic expression of BMAL1 and
CLOCK, providing an essential link between the positive and
negative loops of the circadian clock (Figure 3) (Charoensuksai
and Xu, 2010; Solt et al., 2011a). The PPARs and core clock
genes have been demonstrated to crossregulate transcriptional
outputs in peripheral tissues (Canaple et al., 2006; Gatfield et al.,
2009; Nakamura et al., 2008; Oishi et al., 2005; Wang et al.,
2008), and CLOCK mutant mice have been shown to disrupt
the circadian expression of PPARa in the liver (Lemberger
et al., 1996; Oishi et al., 2005). Rev-erbs (a and b isoforms) and
RORs (a and g isoforms) are coexpressed in adipose tissue, liver,
skeletal muscle, and brain (Bonnelye et al., 1994; Dumas et al.,
1994; Forman et al., 1994; Moore et al., 2006). As monomers,
both Rev-erbs and RORs occupy the same RORE ‘‘half-site’’
with a 50 AT-rich region preceding the response element (Har-
ding and Lazar, 1993, 1995; Moraitis andGigue`re, 1999). The oc-
cupancy of the RORE is synergized between Rev-erbs acting as198 Cell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc.constitutive repressors and RORs as
constitutive activators to fine-tune the
expression of BMAL1, CLOCK, and
several other oscillating gene networks
involved in glucose and lipid metabolism
(Cho et al., 2012; Guillaumond et al.,
2005; Jetten, 2009; Sato et al., 2004;
Solt et al., 2010). Here we review the cur-
rent understanding of the ROR and Rev-erb NR subfamilies’ role in metabolic disorder, and the most
recent efforts to develop synthetic ligand modulators to serve
as chemical probes and therapeutics.
Therapeutic Targeting of RORs for Metabolic Syndrome
The first member of the ROR subfamily of receptors (RORa) was
identified based on sequence similarities to the retinoic acid re-
ceptor (RAR) and the RXR, yielding the name ‘‘retinoic acid
receptor-related orphan receptor’’ (Gigue`re et al., 1994). Two
other members of this NR subfamily, RORb and RORg, were
subsequently identified (Hirose et al., 1994). The RORs display
distinct patterns of tissue expression and are involved in the
regulation of various physiological processes. RORa is predom-
inantly expressed in lung, muscle, brain, heart, peripheral blood
leukocytes, spleen, liver, and ovary, whereas expression of
RORb is limited to the central nervous system (Andre´ et al.,
1998a, 1998b). Two isoforms of RORg are found in both humans
and mice (RORg1 and RORg2), with RORg2 commonly referred
to as RORgt, as it was originally identified in the thymus (Jetten
et al., 2001), although its expression is not limited to T cells.
RORgt, specifically RORgt2, is highly expressed in immune tis-
sue including the thymus, but there is also significant expression
of RORg in the liver, skeletal muscle, adipose tissue, and kidney
(Hirose et al., 1994; Jetten, 2009). Given the specific tissue dis-
tribution of each ROR receptor and their potential role in
pathophysiological conditions, there is considerable interest in
developing synthetic ligand modulators as therapeutics.
RORa has been shown to regulate the expression of several
components of the circadian clock system. These include genes
encoding enzymes and transporters involved in nutrient trans-
port and metabolism, cellular cholesterol homeostasis, xenobi-
otic detoxification, and energy balance (Panda et al., 2002).
Furthermore, RORa regulates the expression of apolipoprotein
CIII, a component of HDL and very-low-density lipoprotein that
plays a role in regulation of triglyceride levels and lipoprotein
lipase (LPL) activity (Raspe´ et al., 2001). Genetic, molecular,
and biochemical studies have demonstrated that RORa-
deficient mice develop severe atherosclerosis and have low
HDL-C, hypo-a-lipoproteinemia, muscular atrophy, and height-
ened inflammatory response (Jarvis et al., 2002; Lau et al.,
1999; Steinmayr et al., 1998). More recently, RORa has been
Cell Metabolism
Reviewshown to control the expression of genes involved in lipid
absorption, b-oxidation, cholesterol efflux, and energy expendi-
ture in skeletal muscle cells (C2C12) (Lau et al., 2004). RORa has
also been shown to regulate the expression of FGF21, a potential
pharmacological target gene for treatment of metabolic disease
(Wang et al., 2010).
Observations in the RORasg/sg stagger mouse provide insight
into the role of the receptor in metabolic homeostasis. These
mice, which express nonfunctional RORa, are resistant to diet-
induced obesity (Lau et al., 2008). Analysis of thesemice showed
a significant reduction in the levels of expression of SREBP1c
and FAS. SREBP1 is a critical transcriptional regulator that con-
trols the expression of genes involved in fatty acid biogenesis,
and directly regulates lipogenic enzymes such as FAS (Shimano
et al., 1999). Interestingly, genes related to the thermogenic pro-
gram such as b2-AR, UCP-1, NOR-1, and PGC1(a/b) were
increased in BAT in these mice (Bertin et al., 1990; Crunkhorn
et al., 2007; Lau et al., 2008). These findings suggest that the
development of synthetic RORa agonist/inverse agonist ligands
may hold therapeutic potential for the treatment of metabolic
disorders and in parallel will serve as useful chemical probes to
better understand the receptors’ functional role.
RORg, along with RORa, is expressed in skeletal muscle, a tis-
sue that accounts for approximately 40%of total bodymass and
50% of energy expenditure and is a major site of fatty acid and
glucose oxidation (Rasmussen and Wolfe, 1999). It has been
shown that RORg controls expression of genes that regulate
muscle activity, fat mass, and lipid homeostasis (FABP4,
CD36, and LPL) and plays a role in the regulation of reactive ox-
ygen species (ROS) (Raichur et al., 2007). Microarray analyses of
liver tissue from RORasg/sg, RORg/, and RORsg/sg RORg/
double knockout mice (Kang et al., 2007) revealed that RORa
and RORg are critical regulators of hepatic genes encoding
several phase I and phase II metabolic enzymes, including
3b-hydroxysteroid dehydrogenases, cytochrome P450 en-
zymes, and sulfotransferases. Mice deficient in RORg also
exhibit reduced blood glucose levels (Kang et al., 2007). In dou-
ble knockoutmice, a similar reduction in cholesterol, triglyceride,
and blood glucose levels was observed as compared to single
gene knockout (Kang et al., 2007; Meissburger et al., 2011). As
muscle and liver are critical mediators of insulin sensitivity, lipid
metabolism, and energy balance (Lau et al., 2004; Ramakrishnan
et al., 2005), the pharmacological targeting of RORa and RORg
holds promise for the treatment of metabolic syndrome and
associated diseases.
Ligand Modulation of the RORs
RORa, RORb, and RORg have long been considered orphan
receptors, as endogenous ligands have yet to be unanimously
agreed upon. Regardless, crystal structures of these receptors
bound to naturally occurring ligands have provided insight into
molecules that may be functionally relevant. The first ROR LBD
subtype to be crystallized was RORb in complex with stearic
acid, a prevalent saturated fatty acid (Stehlin et al., 2001). Sub-
sequently, all-trans retinoic acid (ATRA) and a synthetic analog
(ALRT 1550) were identified as functional ligands (Stehlin-Gaon
et al., 2003). RORa LBD crystal structures identified cholesterol
and cholesterol sulfate as potential ligands and served as early
indicators that RORa played a central role in lipid metabolism(Kallen et al., 2002, 2004). It is interesting to note that in spite
of the high sequence similarity and similar-sized ligand binding
pockets (722 A˚3 and 766 A˚3, respectively) of the RORa and
RORb LBDs, cholesterol has no effect on RORb activity.
More recently, the crystal structures of RORg in complex with
20a-, 22R-, and 25- hydroxycholesterol were reported (Jin et al.,
2010). These oxysterols were shown to have agonist activity on
the receptor driving an active AF2 confirmation that facilitates
recruitment of coactivator to the conserved charge clamp
comprised of helices 3, 4, 5, and 12 of the LBD. This finding
served as a critical first step toward designing synthetic RORg
modulators and further suggests the receptors’ role as a central
mediator of metabolism and lipid homeostasis. In contrast, the
crystal structure of RORg in complex with antagonist digoxin,
an extract from the foxglove plant (Digitalis lanata), highlights
the molecular interactions critical for antagonizing coactivator
interaction (Fujita-Sato et al., 2011). This structure reveals that
digoxin protrudes between helices 3 and 11 of the LBD and pre-
vents positioning of helix 12 into an active conformation. These
observations provide a template by which to design synthetic
small-molecule modulators of RORg.
Due to the emerging role of RORs in several human diseases,
considerable efforts have been made to develop synthetic exog-
enous ligands with improved potency, specificity, and pharma-
cokinetics. The synthetic agonist of the liver X receptor (LXR)
T0901317 was the first modest affinity synthetic small molecule
to be identified as a dual RORa/g antagonist/inverse agonist
(Figure 4) (Houck et al., 2004; Kumar et al., 2010b; Li et al.,
2006; Mitro et al., 2007). Removal of the sulfonamide alkyl group
from the T0901317 scaffold resulted in RORa/g antagonists/
inverse agonist devoid of LXR activity (Kumar et al., 2010a;
Solt et al., 2011b). One such example, SR1001, repressed both
RORa-Gal4 and RORg-Gal4 transcriptional activity with
EC50’s 4–6 mm (Solt et al., 2011b). SR1001 inhibited the devel-
opment of murine TH17 cells, as demonstrated by inhibition of
interleukin-17A gene expression and protein production.
Furthermore, SR1001 inhibited the expression of cytokines
(IL17a, IL17f, IL21, and IL22) when added to differentiated
murine or human TH17 cells. Finally, SR1001 effectively delayed
the onset and clinical severity of autoimmune disease in a MOG-
induced mouse model (EAE) of multiple sclerosis. HDX ex-
periments have provided the first structural insight into the
mechanism of transcriptional repression, demonstrating that
SR1001 disrupts interaction with the receptor interacting domain
(RID) of coactivator SRC2 (Solt et al., 2011b).
Further optimization of the T091317 scaffold led to the identi-
fication of SR3335, a RORa selective antagonist/inverse agonist
(Kumar et al., 2010a; Solt et al., 2012a). SR3335 significantly
inhibited the constitutive activity of RORa in a cell-based trans-
activation assay (IC50 = 480 nM) but had no effect on the activity
of LXRa, RORb, and RORg. Diet-induced obese (DIO) mice were
treated with SR3335 for 6 days, and a pyruvate tolerance test
revealed reduced plasma glucose levels compared with
vehicle-treated cohorts. Importantly, mice treated with SR3335
displayed no difference in body weight or food intake after
7 days of treatment, indicating the effects on glucose homeosta-
sis are not secondary to weight loss and represent a metabolic
response. These data suggest SR3335 is a useful chemical
probe for evaluating the in vitro and in vivo functions of RORaCell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc. 199
Figure 4. Evolution of Synthetic RORa/g
Inverse Agonists
Next-generation selective RORa/g duel agonist
and subtype-specific inverse agonists from
T0901317, a synthetic dual RORa/g inverse
agonist with LXR agonist activity. T0901317 RORa
IC50 0.132 mM, RORg 0.051 mM; SR1078 IC50
RORa 1–3 mM, RORg 1–3 mM; SR1001 IC50 RORa
0.172 mM, RORg 0.111 mM; SR3335 IC50
RORa 0.480 mM; SR2211 IC50 RORg 0.320 mM;
SR1555 IC50 RORg 1.5 mM.
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treatment of type 2 diabetes. Optimization of synthetic ligands
for the RORs has recently been reviewed (Kamenecka et al.,
2013). It is particularly interesting that subtle changes to the
same chemical scaffold can yield ROR subtype selective ligands
and alter their pharmacology from antagonists/inverse agonists
to agonists.
Therapeutic Targeting of the Rev-Erbs for Metabolic
Syndrome
The Rev-erb subfamily of NRs consists of two members, Rev-
erba (NR1D1) (Lazar et al., 1989) and Rev-erbb (NR1D2) (Dumas
et al., 1994), similar in protein structure and function. The Rev-
erbs are unique NRs in that they have a truncated C terminus
(devoid of helix 12 of AF2) which prevents association with coac-
tivator proteins (Woo et al., 2007). Importantly, the Rev-erbs
retain the ability to complex with corepressor proteins like
NCoR (Zamir et al., 1996), forming a potent transcriptional
repressor complex that is critical for proper metabolic function.200 Cell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc.Rev-erb proteins are expressed in multi-
ple tissues including adipose, liver, brain,
and skeletal muscle. The orchestrated
expression pattern of Rev-erba in adi-
pose tissue has been demonstrated to
be a critical regulator of adipogenesis
(Chawla and Lazar, 1993; Laitinen et al.,
2005; Wang and Lazar, 2008) and can
be modulated by TZD-induced activation
of PPARg (Fontaine et al., 2003). The Rev-
erbs’ role in lipid metabolism and glucose
homeostasis and involvement in choles-
terol trafficking are also a result of their
ability to modulate key enzymes in each
pathway. Rev-erbs have been reported
to regulate the expression of LPL, an
enzyme involved in the uptake and accu-
mulation of lipids in multiple organs and
cell types (Babaev et al., 1999; Kern,
1997; Ong et al., 1994; Pulinilkunnil and
Rodrigues, 2006). Rev-erba deficiency in
mice elevates LPL levels in peripheral tis-
sues (liver, muscle, and adipose tissue)
correlating with increases in body weight
and overall adiposity (Delezie et al., 2012).
Further, the sterol regulatory element-
binding protein 1c (Srebp-1c) and itstarget gene fatty acid synthase (FAS), key regulators of lipogen-
esis, were reduced upon silencing of Rev-erba (LeMartelot et al.,
2009). Rev-erba deficiency in skeletal muscle leads to reduced
mitochondrial content and oxidative function resulting in
compromised exercise capacity, while overexpression and
pharmacological activation of the receptor led to an improve-
ment (Woldt et al., 2013).
Cholesterol trafficking is partly regulated by Rev-erb proteins
through transcriptional regulation of various lipoproteins.
APOC3, a component of HDL and VLDL that regulates triglycer-
ide levels, is present in high levels in Rev-erba null mice (Coste
and Rodrı´guez, 2002). These same mice also suffer from abnor-
mally high VLDL and triglyceride levels. ApoA1, a significant
component of HDL necessary for the transport of cholesterol
to the liver for excretion into the bile, is repressed by fibrates
(Lefebvre et al., 2009). Fibrates, a class of hypolipidemic drugs
and known PPARa activators, increased Rev-erb mRNA levels
10-fold in rat livers, likely mediated through PPARa transactiva-
tion (Gervois et al., 1999). Rev-erbs also can modulate bile acid
Figure 5. Evolution of Synthetic Rev-Erb Modulators
Generation of synthetic Rev-erb ligands started from the discovery of heme as
an endogenous ligand. To date, various synthetic modulators with altered
function have been developed. GSK4112 EC50 Rev-erba 0.40 mM; SR9009
IC50 Rev-erba 0.67 mM, Rev-erbb 0.80 mM; SR9011 IC50 Rev-erba 0.79 mM,
Rev-erbb 0.56 mM; SR8278 EC50 Rev-erba 0.47 mM.
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(Cyp7A1), the rate-limiting enzyme in the classic pathway of
bile acid synthesis from cholesterol in the liver (Duez et al.,
2008). Mice lacking Rev-erba have asynchronous circadian
rhythms, with a predisposition to diet-induced obesity, impaired
glucose, and lipid utilization leading to increased susceptibility to
diabetes (Delezie et al., 2012; Preitner et al., 2002). Depletion of
both Rev-erb a/b isoforms in mice results in elevated hepatic
triglyceride levels triggering hepatosteatosis (Bugge et al.,
2012). Rev-erbs have been shown to regulate hepatic glucose
production, with increased heme binding demonstrated to
repress the gluconeogenic gene PepCK in HepG2 cells (Yin
et al., 2007). Synthetic modulators of Rev-erbs have been shown
to alter expression of G6Pase, the enzyme controlling the final
step of gluconeogenesis (Grant et al., 2010; Kojetin et al.,
2011). These findings support the role of Rev-erbs in both lipid
and glucose homeostasis, making these receptors attractive tar-
gets of therapeutic intervention for metabolic disorders.
Rev-Erb Ligands
Rev-erba and Rev-erbbwere identified as orphan nuclear recep-
tors based on their conserved NR domain structure and homol-
ogy with other NRs (Bonnelye et al., 1994; Dumas et al., 1994;
Lazar et al., 1989). The identification of the porphorin heme asa physiological ligand capable of regulating receptor function
provided further molecular and mechanistic insights into the
role of Rev-erbs (Burris, 2008; Raghuram et al., 2007; Yin
et al., 2007). Heme binding modulates the repressive activity of
Rev-erb by increasing recruitment of the corepressor NCoR
and HDAC3 to DNA response elements in promoter regions of
Rev-erb target genes (Guillaumond et al., 2005; Kumar et al.,
2010c; Raspe´ et al., 2002; Yin et al., 2007). Heme has also
been shown to promote proteasomal degradation of the re-
ceptor, a critical event for adipogenesis (Kumar et al., 2010c;
Wang and Lazar, 2008). The cocrystal structure of Rev-erbb in
complex with heme shows that a single molecule of the por-
phorin is bound, and it has been demonstrated that the receptor
can adopt multiple conformational states depending on the iron
oxidation state (Marvin et al., 2009; Pardee et al., 2009). Despite
these findings, the utility of heme as a chemical probe to study
the functional effects of Rev-erb ligand binding is limited due
to its cell toxicity at high concentrations and the lack of selectivity
for Rev-erb (Alayash, 2004; Kim et al., 2004).
To address these shortcomings, efforts to develop synthetic
Rev-erb ligands were initiated with the development of a fluores-
cence resonance energy transfer (FRET) biochemical assay
monitoring the interaction between the Rev-erb LBD and a pep-
tide representing the first interaction domain of NCoR (NCoR
1D1) (Grant et al., 2010). Using this assay to screen targeted
chemical libraries, the first synthetic agonist GSK4112 was iden-
tified, and it was shown that this compound enhanced the inter-
action of Rev-erbs with NCoR (Figure 5) (Grant et al., 2010;
Kumar et al., 2010c; Meng et al., 2008). Importantly, GSK4112
was compatible with cellular studies and was shown to inhibit
the expression of the circadian target gene bmal1, to repress
expression of gluconeogenic genes in liver cells, and to reduce
glucose output in primary hepatocytes (Grant et al., 2010).
GSK4112 was also reported to induce adipogenesis in 3T3-L1
cells, leading to increased lipid accumulation and increased
expression of adipogenic genes including aP2, NR1C3, and
AdipoQ (Kumar et al., 2010c). Interestingly, GSK4112 was also
shown to synergize with rosiglitazone in promoting lipid accumu-
lation (Kumar et al., 2010c).
More recently, the Rev-erb agonists SR9009 and SR9011
were described, representing chemical tools with improved
pharmacokinetics over GSK4112 that were sufficient to enable
in vivo studies (Solt et al., 2012b). Treatment of obese mice
with SR9009 resulted in weight loss, improved dyslipidemia,
and improved hyperglycemia. SR9009 and SR9011 were re-
ported to alter gene expression in several tissues including liver,
skeletal muscle, and WAT. In skeletal muscle the Rev-erb
agonists induced expression of genes involved in fatty acid
oxidation and glycolysis such as Cpt1b, Ucp3, Ppargc1b,
Pkm2, andHk1. These Rev-erb agonists also decreased expres-
sion of the lipogenic enzymes Fasn and Scd1 and the cholester-
ologenic regulatory proteins Hmgcr and Srebf2, consistent with
the decreased triglyceride and cholesterol synthesis observed
in liver and WAT from treated animals. Taken together, these
observations suggest Rev-erb agonists increase whole-body
energy expenditure, offering an approach for treatment of meta-
bolic syndrome.
Recently, the first synthetic Rev-erba antagonist (SR8278)
was described to oppose the action of heme and driveCell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc. 201
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2011). SR8278 is structurally similar to the synthetic agonist
GSK4112; however, it too has poor pharmacokinetic properties.
Despite this shortcoming, SR8278 represents a chemical probe
to characterize Rev-erba in cell-based models.
Future Directions and Perspective
The TZD class of PPARg-targeted insulin sensitizers for the
treatment of T2DM had an unfettered decade-long run of com-
mercial and clinical success. However, the long-term safety
concerns associated with this class of drugs have sig-
nificantly increased the scrutiny which all next-generation
PPARg-targeted therapeutics must face. While the TZD pioglita-
zone is still widely used clinically for the treatment of T2DM, its
future is somewhat uncertain as reports of bladder cancer inci-
dence and bone fractures continue to persist (Stephenson,
2011). Nevertheless, PPARg’s role as the ‘‘master regulator of
adipogenesis’’ and the growing need for safe and effective drugs
to treat metabolic syndrome will ensure it remains a target of
interest for pharmacological development. It will be critical for
future development efforts to better understand the complexity
of functional response induced by ligand binding. These can
include the effects of ligand binding on PTM status, oligomeric
state, and cofactor and DNA affinity, in addition to classical
AF2-dependent agonism. Monitoring, in an unbiased fashion,
the expression profile of PPARg target genes in response to a
wide range of pharmacologically distinct ligands will be critical
in delineating function in this increasingly complex, multivariable
system. The development of functional SPPARMs like SR1664
demonstrates how improved understanding of the complex NR
regulatory networks can lead to new approaches to modulate
old targets.
The central role that has emerged for the RORs and Rev-erbs
in regulating the circadian clock and metabolic gene networks
that control glucose and lipid metabolism strongly suggests their
potential for therapeutic targeting for the treatment of metabolic
syndrome. Pharmacological development efforts are still in their
infancy, but the increasing interest in these targets promises that
a wave of synthetic ligands will emerge covering the spectrum of
functional outputs and with optimized pharmacokinetics. If the
lessons learned from PPARg are predictive, it is likely that func-
tional selective ROR and Rev-erb modulators that affect recep-
tor oligomeric state, cofactor and DNA affinities, and PTMs will
be critical for formulating pharmacological strategies and limiting
adverse effects. Functionally relevant PTMs for both Rev-erba
(Yin et al., 2006) and RORa (Ermisch et al., 2011; Hwang et al.,
2009; Lechtken et al., 2007; Lee et al., 2010) have been reported,
and understanding the effect of ligand binding on modulating
these sites will be critical. It has been demonstrated that inhibi-
tion of GSK3b with lithium can destabilize Rev-erba and affect
the circadian clock, potentially leading to its efficacy in circadian
diseases such as bipolar disorder (Yin et al., 2006). Targeting the
NR substrate as opposed to the modifying enzymes, as demon-
strated with PPARg, may prove to be a desirable strategy with
reduced off-target effects. As the complexity of NR biology
comes more into focus, the opportunities to develop mecha-
nism-based, functional selective ligands that translate into ther-
apeutics targeting metabolic syndrome and a variety of other
diseases will continue to emerge.202 Cell Metabolism 19, February 4, 2014 ª2014 Elsevier Inc.REFERENCES
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